Abstract
Abnormal cholinergic neurotransmission has been suggested to occur in psychiatric illness. Therefore, this study investigated cholinergic muscarinic receptors in the anterior cingulate cortex (ACC) of schizophrenia, bipolar disorder and major depression disorder (n=15 per group). We used quantitative autoradiography to measure [3H]pirenzepine binding to M1 and M4 receptors. Brain tissue was obtained from the Stanley Foundation Neuropathology Consortium. [3H]pirenzepine binding was higher in superficial laminae (I–II) than in deep laminae (III–VI) of the ACC. There was a significant 24% reduction in the density of [3H]pirenzepine in the deep laminae and a significant 19% reduction in the upper laminae of the ACC in the schizophrenia group compared to the control group. There were no differences in [3H]pirenzepine binding in any laminae of the ACC in the bipolar or major depression groups compared with the control group, except for a trend towards decreased [3H]pirenzepine binding in subjects with major depression relative to control subjects. We also detected a significant effect of suicide on [3H]pirenzepine binding in the ACC in subjects who died as a result of suicide relative to those who did not, which was more evident in patients with schizophrenia. A significant effect of the onset of the disease was also observed that was more evident in patients with bipolar disorder. The study provides evidence of decreased muscarinic receptor density in the ACC in schizophrenia but no evidence for significant changes in these receptors in the bipolar and major depression groups. The changes observed in schizophrenia may contribute to dysfunctional ACC neural circuits.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Avissar S, Schreiber G (1991). The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders. Biol Psychiatry 31: 435–459.
Benes FM (2000). Emerging principles of altered neural circuitry in schizophrenia. Brain Res Rev 31: 251–269.
Bennett P, Enna SJ, Bylund DB, Gillin C, Wyatt RJ, Snyder SH (1979). Neurotransmitter receptors in frontal cortex in schizophrenia. Arch Gen Psychiatry 36: 927–934.
Buckley NJ, Bonner TI, Brann MR (1989). Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 35: 469–476.
Crook JM, Dean B, Pavey G, Copolov D (1999). The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 64: 1761–1771.
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychol 48: 381–388.
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001). Decreased muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46, and the effects of neuroleptic drug treatment. Am J Psychiatry 158: 918–925.
Dean B, Crook JM, Oeskin K, Hill C, Keks H, Copolov DL (1996). The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1: 54–58.
Dilsaver SC (1986). Cholinergic mechanisms in depression. Brain Res Rev 11: 285–316.
Flynn DD, Mash DC (1993). Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labelling and localization of M1, M2 and M3 muscarinic receptor subtypes in primate brain. Synapse 14: 283–296.
Fritze J (1993). The adrenergic–cholinergic imbalance hypothesis of depression: a review and a perspective. Rev Neurosci 4: 63–93.
Gebhard R, Zilles K, Schleicher A, Everitt BJ, Robbins TW, Divac I (1995). Parcellation of the frontal cortex of the new world monkey Callithrix jacchus by eight neurotransmitter-binding sites. Anat Embryol 191: 509–517.
Holt DJ, Herman MM, Hyde TM, Kleinman JE, Sinton CM, German DC et al (1999). Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 94: 21–31.
Hyde TM, Crook JM (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat 22: 53–63.
Knable MB, Barci BM, Bartko JJ, Webster MJ, Torrey EF (2002). Abnormalities of the cingulate gyrus in bipolar disorder and other severe psychiatric illnesses: postmortem findings from the Stanley Foundation Neuropathology Consortium and literature review. Clin Neurosci Res 2: 171–181.
Mash DC, White WF, Mesulam MM (1998). Distribution of muscarinic receptor subtypes within architectonic subregions of the primate cerebral cortex. J Comp Neurol 278: 265–274.
Meltzer HY, Okayli G (1995). Reduction of suicidality during clozapine treatment of neuroleptic resistance schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152: 183–190.
Mesulam MM (1995). The cholinergic contribution to neuromodulation in the cerebral cortex. Semin Neurosci 7: 297–307.
Meyerson LR, Wennogle LP, Abel MS, Coupet J, Lippa AS, Rauh CE et al (1982). Human brain receptor alterations in suicide victims. Pharm Biochem Behav 17: 159–163.
Owen F, Cross AJ, Lofihouse R, Plulter M (1981). Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatry Scand 3: 20–27.
Piggott M, Owens J, O' Brien J, Paling S, Wyper D, Fenwick J et al (2002). Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNQ and (R,S)-I)QNB to human brain. J Chem Neuroanat 24: 211–223.
Posner MI, Early TS, Reisman E, Pardo PJ, Dhawan M (1988). Asymmetries in hemispheric control of attention in schizophrenia. Arch Gen Psychiatry 45: 814–821.
Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA Egan MF, Pickar D et al (2000). In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 23: 56–68.
Thakore JH, Dinan TG (1996). Neuroendocrine abnormalities in bipolar mania and major depressive illness. Eur Psychiatry 11(Suppl 4): 304s.
Torrey EF, Webster M, Knable M, Johnston N, Yolken RH (2000). The stanley foundation brain collection and neuropathology consortium. Schizophr Res 44: 151–155.
Vogt BA, Nimchinsky EA, Vogt LJ, Hof PR (1995). Human cingulate cortex: surface features, flat maps and cytoarchitecture. J Comp Neurol 359: 490–506.
Watanabe S, Nishikawa T, Takashima M, Toru M (1983). Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 33: 2187–2196.
Whitlock FA (1977). Depression and suicide. In: Burrows GD (ed). Handbook of Studies on Depression. Excerpta Medica: Amsterdam, 379–403.
Zavitsanou K, Huang XF (2002). Decreased [3H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study. Neuroscience 109: 709–716.
Zavitsanou K, Ward P, Huang XF (2002). Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 27: 826–833.
Acknowledgements
This work was supported by an Australian Institute of Nuclear Science and Engineering (AINSIE) award to KZ and the Neuroscience Institute of Schizophrenia and Allied Disorders (NISAD; http://www.nisad.org.au), which is supported by infrastructure funding from NSW Health. We wish to thank Ms Kelly Newell for assistance on the day of the experiment. Post-mortem brain tissue was kindly donated by the Stanley Foundation Brain bank courtesy of Drs Michael Knable, E Fuller Torrey, Maree J Webster, and Robert Yolken.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Katerina, Z., Andrew, K., Filomena, M. et al. Investigation of M1/M4 Muscarinic Receptors in the Anterior Cingulate Cortex in Schizophrenia, Bipolar Disorder, and Major Depression Disorder. Neuropsychopharmacol 29, 619–625 (2004). https://doi.org/10.1038/sj.npp.1300367
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300367
Keywords
This article is cited by
-
Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia
Neuropsychopharmacology (2021)
-
Functional coupling of M1 muscarinic acetylcholine receptor to Gαq/11 in dorsolateral prefrontal cortex from patients with psychiatric disorders: a postmortem study
European Archives of Psychiatry and Clinical Neuroscience (2020)
-
Neuropathological changes in the nucleus basalis in schizophrenia
European Archives of Psychiatry and Clinical Neuroscience (2013)
-
Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
Neuropsychopharmacology (2012)
-
Muscarinic Receptor Occupancy and Cognitive Impairment: A PET Study with [11C](+)3-MPB and Scopolamine in Conscious Monkeys
Neuropsychopharmacology (2011)
